US 12128109
Muscle targeting complexes and formulations for treating dystrophinopathies
granted A61KA61K2039/505A61K47/545
Quick answer
US patent 12128109 (Muscle targeting complexes and formulations for treating dystrophinopathies) held by Dyne Therapeutics, Inc. expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Dyne Therapeutics, Inc.
- Grant date
- Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K2039/505, A61K47/545, A61K47/548, A61K47/65